Bioiberica will be attending the DCAT week in New York
it is one of the largest gatherings in the world for the pharmaceutical and related industries
Bioiberica Heparin Science Business Unit will be attending the DCAT Week in New York City from March 16th through 19th, 2015. The DCAT week is one of the largest gatherings in the world for the pharmaceutical and related industries. It brings together company presidents, CEOs, sales, marketing, business development, supply management and representatives involved in any aspect of the pharmaceutical manufacturing industry for high-level meetings and networking events.
The production of heparin was the company´s first venture. The purposes of the Heparin Science business unit are to reinforce leadership in heparin production, to increase the molecule supply potential, prioritizing safety and traceability, and to explore new applications, as well as new projects and developments. Currently, one in five doses administered worldwide is developed and manufactured by Bioibérica.
Related News
The 28th Symposium on Glycosaminoglycans, an internationally renowned scientific event focusing on glycosaminoglycans, will be sponsored by
- Bioiberica produces 20% of the world's Heparin API.
- Heparin saves around a hundred million lives every year.
- One out of every 5 doses of heparin administered in the world comes from Bioiberica.
- One of every 5 doses of heparine administered in the world comes from Bioiberica.
- Several studies indicate that people hospitalized treated with anticoagulants, improved their chances of survival.